Your shopping cart is currently empty

BH3I-1 (BHI1) is a Bcl-2 antagonist.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $33 | In Stock | In Stock | |
| 5 mg | $52 | In Stock | In Stock | |
| 10 mg | $85 | In Stock | In Stock | |
| 25 mg | $158 | In Stock | In Stock | |
| 50 mg | $263 | In Stock | In Stock | |
| 100 mg | $428 | In Stock | In Stock |
| Description | BH3I-1 (BHI1) is a Bcl-2 antagonist. |
| Targets&IC50 | BH3-BCL XL:2.4 μM(Ki), MDM2-p53:5.3 μM(Kd) |
| In vitro | BH3I-1 inhibits Bcl-xL heterodimerization in vitro. It also induces cytochrome c release[1]. BH3I-1, while inhibiting its reported target Bcl-2/Bim and Bcl-xL/Bim, shows significant inhibition of both the p53/hDM2 and p300/Hif-1a interactions[2]. |
| Cell Research | Cells (5×104 cells per well) are seeded into white 96-well plates (Costar) and treated with various concentrations of the compounds for 48 h. For zVAD-FMK protection experiments, cells are preincubated with 100 μM zVAD-FMK for 1 h before the addition of chemicals. Cell viability is determined with an MTS assay. For PI staining experiments, cells are grown in 24-well plates and then incubated with 2 μg ml/L PI. Cell death is determined by FACS analysis.(Only for Reference) |
| Synonyms | BHI1 |
| Molecular Weight | 400.31 |
| Formula | C15H14BrNO3S2 |
| Cas No. | 300817-68-9 |
| Smiles | CC(C)C(N1C(=S)S\C(=C\c2ccc(Br)cc2)C1=O)C(O)=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 60 mg/mL (149.88 mM), Sonication is recommended. Ethanol: 11 mg/mL (27.48 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.